10 December 2018 2 Min Read
China biotech company targets $414m in Hong Kong IPO
Shanghai Junshi Biosciences attracted by new rules allowing biotech firms with no revenue or profit to list on city’s stock market
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In